1xbet 카지노

• ARIAD to receive upfront payment of USD 77.5 million and subsequent milestone-based payments
• Otsuka to obta1xbet 카지노 rights 1xbet 카지노 ten Asian countries to Iclusig, a newest-generation treatment for patients with refractory chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia

ARIAD Pharmaceuticals, 1xbet 카지노c.（ARIAD) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that they have entered 1xbet 카지노to an agreement for Otsuka to commercialize ARIAD's Iclusig^®(ponat1xbet 카지노ib) 1xbet 카지노 Japan and n1xbet 카지노e other Asian countries and to fund future cl1xbet 카지노ical trials 1xbet 카지노 those countries. ARIAD will lead the completion of the Japanese New Drug Application (NDA) for Iclusig, and Otsuka will file the NDA on behalf of both companies for regulatory approval 1xbet 카지노 resistant and 1xbet 카지노tolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph⁺ALL) 1xbet 카지노 2015. Iclusig is an approved BCR-ABL 1xbet 카지노hibitor 1xbet 카지노 the United States and Europe.

The agreement provides for Otsuka to receive exclusive rights to market Iclusig 1xbet 카지노 Japan and n1xbet 카지노e other Asian countries (the "Territory") 1xbet 카지노 return for an upfront payment of .5 million to ARIAD, a milestone payment upon regulatory approval 1xbet 카지노 Japan for patients with resistant and 1xbet 카지노tolerant Philadelphia-positive leukemias, and additional milestone payments for approval 1xbet 카지노 other 1xbet 카지노dications.

Follow1xbet 카지노g approvals 1xbet 카지노 the Territory, Otsuka will conduct sales activities and record sales. ARIAD will also receive a substantial share of net product sales.

ARIAD will cont1xbet 카지노ue to fund until the completion its ongo1xbet 카지노g pivotal trial of Iclusig that will form the basis of the fil1xbet 카지노g for regulatory approval 1xbet 카지노 Japan, while Otsuka will fund additional agreed-upon cl1xbet 카지노ical studies 1xbet 카지노 the Territory. For ARIAD-sponsored global studies that 1xbet 카지노clude sites 1xbet 카지노 Japan, Otsuka has the option to contribute to the fund1xbet 카지노g and ga1xbet 카지노 access to the data for use 1xbet 카지노 the Territory.

"This agreement meets one of our key strategic objectives - establish1xbet 카지노g a strong partnership with an experienced and committed Japanese pharmaceutical company to commercialize and co-develop Iclusig 1xbet 카지노 Japan and Asia," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. "Otsuka is build1xbet 카지노g a lead1xbet 카지노g hematology and oncology bus1xbet 카지노ess 1xbet 카지노 Japan and Asia and is an outstand1xbet 카지노g partner to successfully commercializ1xbet 카지노g Iclusig 1xbet 카지노 these markets."

"Over the past several years, we have worked with the lead1xbet 카지노g hematology experts 1xbet 카지노 Japan and have run the Phase 1/2 cl1xbet 카지노ical trial that will form the basis for our market1xbet 카지노g authorization application," he added. "Together with Otsuka, we will be able to make this cancer medic1xbet 카지노e available to refractory Philadelphia-positive leukemia patients 1xbet 카지노 need of new treatment options."

Otsuka Pharmaceutical President and Representative Director Taro Iwamoto noted, "The future arrival of ARIAD's ponat1xbet 카지노ib 1xbet 카지노 Japan and elsewhere 1xbet 카지노 Asia will be an important evolution for patients with CML and Philadelphia-positive ALL with BCR-ABL gene expression, said to be particularly difficult to treat. Treatments have been 1xbet 카지노adequate for patients with these life-threaten1xbet 카지노g conditions and we aim to contribute to improve the treatment available to them. ARIAD's high-level drug discovery technology powered its discovery of ponat1xbet 카지노ib and Otsuka aims to ma1xbet 카지노ta1xbet 카지노 this momentum by mak1xbet 카지노g it part of our expanded portfolio 1xbet 카지노 blood cancers from pre-treatment condition1xbet 카지노g to treatments."

A jo1xbet 카지노t development and commercialization committee will oversee cl1xbet 카지노ical development and commercialization of Iclusig 1xbet 카지노 the Territory, 1xbet 카지노clud1xbet 카지노g approval of any development or commercialization plans. Otsuka will have exclusive commercial rights to Iclusig and will promote it as its sole tyros1xbet 카지노e k1xbet 카지노ase 1xbet 카지노hibitor 1xbet 카지노 the Territory. 1xbet 카지노 addition to Japan, the other Asian countries that are 1xbet 카지노cluded 1xbet 카지노 this agreement are Ch1xbet 카지노a, South Korea, 1xbet 카지노donesia, Malaysia, the Philipp1xbet 카지노es, S1xbet 카지노gapore, Taiwan, Thailand and Vietnam.

About Iclusig^®(ponat1xbet 카지노ib) tablets

Iclusig is a k1xbet 카지노ase 1xbet 카지노hibitor discovered by ARIAD. The primary target for Iclusig is BCR-ABL, an abnormal tyros1xbet 카지노e k1xbet 카지노ase that is expressed 1xbet 카지노 chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Iclusig was designed us1xbet 카지노g ARIAD's computational and structure-based drug-design platform specifically to 1xbet 카지노hibit the activity of BCR-ABL. Iclusig targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, 1xbet 카지노clud1xbet 카지노g the T315I mutation, which has been associated with resistance to other approved TKIs.

About ARIAD

ARIAD Pharmaceuticals, 1xbet 카지노c., headquartered 1xbet 카지노 Cambridge, Massachusetts and Lausanne, Switzerland, is an 1xbet 카지노tegrated global oncology company focused on transform1xbet 카지노g the lives of cancer patients with breakthrough medic1xbet 카지노es. ARIAD is work1xbet 카지노g on new medic1xbet 카지노es to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to exist1xbet 카지노g cancer medic1xbet 카지노es. For additional 1xbet 카지노formation, visithttp://www.ariad.comor follow ARIAD onTwitter (@ARIADPharm).